Treating the kidney to cure the heart

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Cravedi, Paolo ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Cardiovascular disease; Chronic renal disease; Hypertension; Prevention; Proteinuria; Reninangiotensin system inhibitors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DEVELOPING COUNTRY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC REGULATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CHRONIC DISEASE; HYPERLIPIDEMIA; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 57049131488     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.511     Document Type: Conference Paper

References (15)

1. World Health Statistics 2007. Available at http://www.who.int/whosis/ whostat/2007/en/index.html. Accessed on 15 June 2008.
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
4. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
5. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65.
6. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101: 441-454.
7. Pisoni R, Ruggenenti P, Sangalli F et al. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney Int 2002; 62: 1010-1019.
8. Ruggenenti P, Perna A, Mosconi L et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
9. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999; 10: 997-1006.
10. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006; 17: S90-S97.
11. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
12. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
13. Ruggenenti P, Perticucci E, Cravedi P et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-1224.
14. Perico N, Amuchastegui SC, Colosio V et al. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994; 5: 1139-1146.
15. Codreanu I, Perico N, Sharma SK et al. Prevention programmes of progressive renal disease in developing nations. Nephrology (Carlton) 2006; 11: 321-328.